BIIB · News · 20260806N
Acquisition / Partnership / Divestiture
BIOGEN INC. · 2026-08-06 · Importance 71 · Surprise 60 · In source text
Biogen completed its acquisition of RayThera, Inc. on August 6, 2026, expanding its immunology portfolio with multiple small-molecule assets. The transaction carries total consideration of up to $1 billion, comprising $225 million in upfront cash and $775 million contingent on future clinical and regulatory milestones. RayThera’s lead program entered Phase 1 development in July 2026, and Biogen will oversee development, manufacturing, and global commercialization of the acquired assets. The deal is Biogen’s third significant immunology transaction in 2026 and supports its strategy to diversify into oral immunology therapies.
Key facts
- Biogen Inc. has completed the acquisition of RayThera, Inc. for a total consideration of $1 billion. source
- The deal includes an upfront cash payment of $225 million and an additional $775 million contingent on future clinical and regulatory milestones. source
- This acquisition, which excludes certain preclinical assets of RayThera, was finalized on August 6, 2026. source
- The acquisition excludes certain preclinical assets of RayThera. source
- The acquisition is set to bolster Biogen's immunology portfolio by adding several assets, with the lead program already in Phase 1 development. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| assets | positive | realized | — | Biogen Inc. has completed the acquisition of RayThera, Inc. for a total consideration of $1 billion. |
| cash | negative | realized | — | The deal includes an upfront cash payment of $225 million and an additional $775 million contingent on future clinical and regulatory… |
| liability | negative | contingent | — | The deal includes an upfront cash payment of $225 million and an additional $775 million contingent on future clinical and regulatory… |